FindTrial
Sign In

GEN1042 DP

DRUG2 trials

Sponsors

Genmab A/S

Conditions

Head and neck squamous cell carcinoma (HNSCC)Malignant solid tumors: Patients with relapsed or refractoryMetastatic Solid Malignant tumorsNon-Small Cell Lung Cancer (NSCLC)Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).advanced and/or metastatic melanoma

Phase 1

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Active, not recruitingCTIS2023-508526-10-00
Genmab A/Sadvanced and/or metastatic melanoma, Head and neck squamous cell carcinoma (HNSCC), Malignant solid tumors: Patients with relapsed or refractory +2
Start: 2019-10-01Target: 270Updated: 2026-01-27
A Phase 1 Dose Finding and Phase 2 Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
CompletedCTIS2023-508529-29-00
Genmab A/SMetastatic Solid Malignant tumors
Start: 2023-03-08End: 2025-08-11Target: 88Updated: 2025-03-24